Hims & Hers Health, Inc. (NYSE:HIMS) Receives Average Rating of “Hold” from Brokerages

Hims & Hers Health, Inc. (NYSE:HIMS) has received a consensus rating of “Hold” from the fifteen brokerages that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $37.31.

Several equities analysts have recently weighed in on HIMS shares. Morgan Stanley lowered shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and increased their price objective for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. Bank of America increased their price target on shares of Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a report on Tuesday, March 18th. Canaccord Genuity Group boosted their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, February 19th. BTIG Research started coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Finally, Leerink Partners lifted their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a report on Tuesday, February 25th.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Soleil Boughton sold 4,152 shares of Hims & Hers Health stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total value of $251,984.88. Following the transaction, the insider now owns 157,345 shares in the company, valued at approximately $9,549,268.05. This trade represents a 2.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Michael Chi sold 7,259 shares of Hims & Hers Health stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $24.07, for a total value of $174,724.13. Following the completion of the transaction, the insider now owns 193,601 shares in the company, valued at approximately $4,659,976.07. This represents a 3.61 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 998,244 shares of company stock valued at $35,662,485 in the last ninety days. 17.71% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in HIMS. Crewe Advisors LLC acquired a new stake in shares of Hims & Hers Health during the 4th quarter valued at $28,000. Raleigh Capital Management Inc. boosted its stake in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares in the last quarter. Blume Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Smartleaf Asset Management LLC increased its stake in shares of Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after buying an additional 1,413 shares during the period. Finally, Summit Securities Group LLC bought a new position in Hims & Hers Health in the 4th quarter valued at approximately $38,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS opened at $37.06 on Wednesday. The company has a 50-day simple moving average of $39.66 and a 200 day simple moving average of $29.22. The company has a market capitalization of $8.23 billion, a P/E ratio of 84.23 and a beta of 1.37. Hims & Hers Health has a 52-week low of $11.20 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. As a group, equities analysts forecast that Hims & Hers Health will post 0.29 earnings per share for the current year.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.